Roche discontinues Huntington's disease gene-silencing programmes
Roche has ended its gene-silencing efforts targeting Huntington's disease, a setback for a field that has seen several high-profile programme failures in recent years.
Roche has discontinued its gene-silencing programmes aimed at Huntington's disease, according to reporting by STAT News. The decision marks another significant setback for therapeutic strategies targeting the HTT gene in Huntington's disease, a fatal, progressive neurodegenerative condition caused by a CAG trinucleotide repeat expansion.
Gene-silencing approaches — which include antisense oligonucleotides (ASOs) and RNA interference (RNAi) strategies — aim to reduce production of the mutant huntingtin protein. Roche's tominersen, an ASO, was halted at Phase III in 2021 following a futility review; the nature and scope of the programmes now being closed were not detailed in the lede available to Genetic Current.
The news is reported alongside an ARPA-H bespoke gene-therapy initiative (covered separately in a recent Genetic Current cluster from 10 July 2026) and commercial updates from Lilly and Novo. The STAT News item is behind a STAT+ paywall, limiting the detail available for this summary.
The discontinuation underscores the difficulty of translating gene-silencing strategies for central nervous system conditions into effective therapies, and will be of interest to researchers and clinicians following the hereditary neurodegeneration space.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Roche, a large pharmaceutical company, has stopped work on treatments that aimed to silence the faulty gene responsible for Huntington's disease. Huntington's disease is an inherited condition caused by a change in a gene called HTT, which leads to progressive damage to the brain and nervous system.
The type of treatment Roche was developing is called gene silencing — the idea is to reduce the amount of harmful protein the faulty gene produces. Several similar programmes from other companies have also been stopped in recent years, showing how difficult it is to develop effective treatments for this condition.
Researchers around the world continue to explore different approaches to treating Huntington's disease, and the field remains active.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-07-10STAT+: Roche ends Huntington's gene-silencing programs